4.6 Article

Loss of β-arrestin2 mediates pancreatic-islet dysfunction in mice

Journal

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2013.04.079

Keywords

beta-Arrestin2; Insulin secretion; Hyperglycemic clamp; Exocytosis

Funding

  1. National Natural Science Foundation [30971121]
  2. Shanghai Committee of Science and Technology [11140900900]
  3. Wuxi Research Institute of Shanghai Jiao Tong University [2011JDZX023]

Ask authors/readers for more resources

Insulin resistance and defective insulin secretion are two major factors contributing to the pathogenesis of type 2 diabetes. beta-Arrestin2 is known to interact with numerous signaling molecules. Our previous study demonstrated that beta-arrestin2 regulates insulin sensitivity in both skeletal muscle and liver, yet its role in insulin secretion remains elusive. In this study, we found that beta-arrestin2 was abundantly expressed in mouse pancreatic beta cells, while its expression was significantly decreased in obese and diabetic mouse models. Hyperglycemic clamp study showed that the acute and late phase of insulin secretion were impaired in beta-arrestin2 knockout mice. Ex vivo study showed that beta-arrestin2 deficient pancreatic islets exhibited blunted glucose-stimulated insulin secretion. Further analysis demonstrated the number of docked insulin granules in beta-arrestin2 deficient islets was markedly decreased compared to wild-type islets, while insulin content and beta cell mass remained unchanged. Our study establishes a new role for beta-arrestin2 in beta-cell functions, and suggests that the down regulation of beta-arrestin2 may contribute to impaired insulin secretion in type 2 diabetes. (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available